Loading clinical trials...

Shorter Radiation Schedule for the Treatment of Prostate Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Shorter Radiation Schedule for the Treatment of Prostate Cancer

A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer

NCT00201916•Ontario Clinical Oncology Group (OCOG)

View on ClinicalTrials.gov

Summary

To improve the management of patients with early stage prostate cancer.

Detailed Description

To compare the efficacy of a shorter radiation fractionation schedule to the prostate (5250 cGy/20 fractions over 28 days) with a conventional schedule (6600 cGy/33 fractions over 45 days) in men receiving radiotherapy for Stage T1a moderately or poorly differentiated, or T1b, T1c, or T2 prostate cancer. The primary outcome is local control in the prostate and secondary outcomes include toxicity, disease free survival, survival, quality of life and economics.

Eligibility

Age

All ages

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•histologic diagnosis of adenocarcinoma of the prostate with no evidence of metastatic disease to the nodes, bone or lung
•stage T1a moderately or poorly differentiated, T1b, T1c or T2 by the current UICC-TNM classification

Exclusion Criteria

•PSA \> 40 mcg/L
•previous therapy for carcinoma of the prostate other than biopsy or TURP, including patients previously on hormone therapy for treatment of their prostate cancer
•prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured
•simulated volume exceeds 1000 cm3
•previous pelvic radiotherapy
•inflammatory bowel disease
•serious non-malignant disease which would preclude radiotherapy or surgical biopsy
•geographic inaccessibility for follow-up
•psychiatric or addictive disorder which would preclude obtaining informed consent or adherence to protocol
•unable to commence radiation therapy within 26 weeks of the date of last prostatic biopsy
+1 more criteria

Locations (16)

B.C. Cancer Agency - Fraser Valley Cancer Centre

Surrey, British Columbia, Canada

B. C. Cancer Agency - Vancouver Cancer Clinic

Vancouver, British Columbia, Canada

CancerCare Manitoba

Winnipeg, Manitoba, Canada

Dr. Leon Richard Oncology Centre

Moncton, New Brunswick, Canada

Saint John Regional Hospital

Saint John, New Brunswick, Canada

Newfoundland Cancer Clinic

St. John's, Newfoundland and Labrador, Canada

Nova Scotia Cancer Centre

Halifax, Nova Scotia, Canada

Northeastern Ontario Regional Cancer Centre

Greater Sudbury, Ontario, Canada

Juravinski Cancer Centre

Hamilton, Ontario, Canada

Cancer Centre of Southeastern Ontario at Kingston General Hospital

Kingston, Ontario, Canada

Key Dates

Start Date

March 1, 1995

Primary Completion Date

December 1, 2008

Completion Date

December 1, 2009

Last Updated

August 17, 2010

Enrollment

936

ACTUAL participants

Conditions

Prostate Cancer

Interventions

5250 cGy/20 fractions over 28 days

PROCEDURE

6600 cGy/33 fractions over 45 days

PROCEDURE

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Shorter Radiation Schedule for the Treatment of Prostate Cancer

Inclusion Criteria

Exclusion Criteria

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC